Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

NeuroVive Pharmaceutical AB. (2/18/15). "Press Release: Year-End Report 1 Jan. 2014 till 31 Dec. 2014".

Organisations Organisation NeuroVive Pharmaceutical AB
  Group NeuroVive (Group)
  Organisation 2 NeuroVive Pharmaceutical Asia Inc. (NeuroVive Asia)
  Group NeuroVive (Group)
Products Product CicloMulsion®
  Product 2 NeuroStat®
     


Fourth Quarter (1 Oct. 2014 – 31 Dec. 2014)

Net revenues were SEK 0 (0) and other operating income was SEK 8,000 (12,000).
Loss before tax was SEK -17,346,000 (9,169,000).
Earnings per share* were SEK -0.59 (-0.45).
Diluted earnings per share** were SEK -0.59 (-0.45).Twelve Months (1 Jan. 2014 – 31 Dec. 2014)

Net revenues were SEK 7,152,000 (5,335,000) and other operating income was SEK 1,181,000 (1,598,000).
Loss before tax was SEK -44,673 (-22,126,000).
Earnings per share* were SEK -1.53 (-1,17).
Diluted earnings per share** were SEK -1.53 (-1,17).

* Proft/loss for the period divided by the average number of shares before dilution at the end of the period.
**Profit/loss for the period divided by the average number of shares after dilution at the end of the period.

Business highlights in the fourth quarter of 2014

NeuroVive and Skåne University Hospital has initiated a collaboration to complete a clinical phase II study on the evaluation of the company’s product CicloMulsion® regarding its ability to prevent acute kidney injury in 150 patients undergoing heart surgery. Enrolment to the study will begin in the first half of 2015 and is expected to continue until the end of 2016.

Post balance sheet events

NeuroVive has established a subsidiary in Taiwan, NeuroVive Pharmaceutical Asia, Inc., which has secured initial funding totaling USD 3,255 m. The funding is sourced from Taiwanese investors, collaboration partner Foundation Asia Pacific Ltd. and the parent company ahead of its potential IPO in Taiwan. The subsidiary strengthens the group’s presence in Asia and will be the driver behind existing project in the region, while conducting its own research and development operations under license from the parent company.


Read the Year-End Report attached below


NeuroVive Pharmaceutical AB (publ) is obligated to publish the information contained in this news release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 08:30 a.m. CEST on 18 February 2015.

NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTC Grey Market. Investors can find Real-Time quotes and market information for the company at www.otcmarkets.com/stock/NEVPF/quote



[ full release at http://mb.cision.com/Main/6574/9725979/345567.pdf ]

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for NeuroVive (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top